ALI/ARDS Clinical Sub-phenotyping Study

Launched by CHINA-JAPAN FRIENDSHIP HOSPITAL · Nov 8, 2023

Keywords

ClinConnect Summary

The ALI/ARDS Clinical Sub-phenotyping Study is a clinical trial focused on understanding and improving treatment for patients suffering from Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS). The goal of this study is to gather detailed information about Chinese patients who have ARDS, which will help researchers identify different patient groups. By doing this, they aim to tailor treatments more effectively to individual patients, ultimately leading to better health outcomes.

To participate in this study, you need to be at least 18 years old and meet the updated diagnostic criteria for ARDS. If you or a loved one are eligible and choose to participate, you will be asked to provide consent to join the study. As a participant, you can expect to contribute to important research that could lead to improved care for ARDS patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Meet the diagnostic criteria for Acute Respiratory Distress Syndrome (ARDS) according to the updated global definition in 2023.
• • The patient or their legal representative signs an informed consent form.
• Exclusion Criteria:
• • Individuals aged less than 18 years old.
• • Those who refuse to participate in the study.